The micro-cap biotech, with a market cap worth less than $20 million and trading in penny stock territory, said its board is “exploring the potential for an acquisition, company sale, merger, business …
More Aerpio may hang the ‘for sale’ sign up, axes CEO after eye drug flop Videos